PATH | VRL
Menu

Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus From Birth

This article, published in The New England Journal of Medicine, reports the results of a study in Indonesia to evaluate the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB). Healthy newborns received three doses of the vaccine, which was administered according to a neonatal vaccine schedule or an infant schedule, or placebo. The study found that the vaccine efficacy was 75 percent in the neonatal schedule group, 51 percent in the infant-schedule group, and 63 percent in the neonatal-schedule and infant-schedule groups combined. The authors concluded that RV3-BB was efficacious in preventing severe rotavirus gastroenteritis when administered according to a neonatal or an infant schedule.

Author: Bines JE, Thobari JA, Satria CD, et al.

Published: 2018

» Visit web page (English)

(Located at www.nejm.org)

Citation: Bines JE, Thobari JA, Satria CD, et al. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth. The New England Journal of Medicine. 2018;378:719–730.

Resource types: Peer-reviewed journal

Diseases/vaccines: Rotavirus

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Asia